Robert C Doebele

15PUBLICATIONS
78CO-AUTHORS
Molecular targetsCancer cell biologyEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Oct 22, 2026
Allosteric Inhibition of TrkB Activation as Related to Neuroblastoma by Triazole Bridged Compounds.

|Dec 23, 2025
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.

Qianqian Hu, Lily L Remsing Rix, Bina Desai

|Aug 11, 2025
Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results.

Ecaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder

|Nov 03, 2024
Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance.

David Gonzalez-Martinez, Lee Roth, Thomas R Mumford

|Sep 25, 2023
MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.

Nan Chen, Logan C Tyler, Anh T Le

|Apr 20, 2022
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.

Gaia Bianco, Mairene Coto-Llerena, John Gallon

Pageof 3

Frequent Collaborators

2 joint publications

Tejas Patil

2 joint publications

Niko Beerenwinkel

2 joint publications

Sumana Srivatsa

2 joint publications

Claudia Lengerke